Suppr超能文献

常见可变免疫缺陷症的健康政策:疾病负担。

Health policy for common variable immunodeficiency: burden of the disease.

机构信息

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

J Investig Allergol Clin Immunol. 2011;21(6):454-8.

Abstract

BACKGROUND

Common variable immunodeficiency (CVID) is a primary immunodeficiency disease characterized by recurrent infections and increased susceptibility to autoimmunity and malignancy.

OBJECTIVES

This study was performed to estimate the burden of CVID in Iran during 1985-2008 based on incidence, mortality, and disability-adjusted life-years (DALY).

METHODS

The methods developed by the World Health Organization for national burden of disease studies were applied to estimate the incidence of disease and thus calculate the years of life lost due to premature mortality (YLL), years living with disability (YLD), and DALYs.

RESULTS

The average age-adjusted incidence of CVID was 1 case per 200 000 per year; the average age-adjusted prevalence was 1 case per 91 000 per year. The burden of CVID (DALYs) was 25.21 years per 100000 individuals (17.86 for YLL and 7.35 for YLD). DALYs increased significantly in patients aged 5-14 years and in those with polyclonal lymphocytic infiltration phenotypes (P < .001).

CONCLUSIONS

Based on the measurement of DALY in patients with CVID, reducing the rate of premature death in the polyclonal lymphocytic infiltration phenotype and the rate of infectious episodes in patients with the infectious only phenotype and appropriate management with regular intravenous immunoglobulin represent the best approach to decreasing the burden of CVID.

摘要

背景

普通变异性免疫缺陷(CVID)是一种以反复感染和增加自身免疫及恶性肿瘤易感性为特征的原发性免疫缺陷病。

目的

本研究旨在根据发病率、死亡率和伤残调整生命年(DALY)来评估 1985 年至 2008 年期间伊朗的 CVID 负担。

方法

应用世界卫生组织用于国家疾病负担研究的方法来估计疾病的发病率,从而计算因过早死亡导致的生命年损失(YLL)、残疾生存年(YLD)和 DALY。

结果

平均年龄校正后的 CVID 发病率为每年每 200000 人中有 1 例;平均年龄校正后的患病率为每年每 91000 人中有 1 例。CVID 的负担(DALY)为每 100000 人 25.21 年(17.86 年用于 YLL,7.35 年用于 YLD)。5-14 岁患者和多克隆淋巴细胞浸润表型患者的 DALY 显著增加(P<0.001)。

结论

根据 CVID 患者的 DALY 测量,减少多克隆淋巴细胞浸润表型患者的过早死亡率和仅感染表型患者的感染发作率,并通过定期静脉注射免疫球蛋白进行适当管理,是降低 CVID 负担的最佳方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验